Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of DC371739 in Hypercholesterolemic Subjects
NCT04927221Phase 1Completed
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing DC371739 with Placebo (2 arms). Primary endpoints: Tolerability evaluation at Day 42, Safety evaluation at Day 42 and 1 more. Started Apr 2021; status: completed.
02
Drugs
pingvakatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04927221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927221.